AKAGERA Medicines Inc, a biotech company developing novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu, RSV and other infectious diseases, announced on Tuesday that it has completed the first cohort in its first-in-human phase 1 SAD/MAD study of AKG-100.

AKG-100 is an oxazolidinone class of antibiotic intended for treatment of pulmonary tuberculosis (TB).

The study consists of single ascending dosing (SAD) and multiple ascending dosing (MAD) to establish the safety and pharmacokinetics of AKG-100 alone in single doses in healthy volunteers and pulmonary TB patients as well as in multiple doses in pulmonary TB patients. Approximately 100 participants will be enrolled in the study, which is being conducted at TASK clinical research site in Cape Town, South Africa..

AKAGERA Medicines is supported by the Coalition for Epidemic Preparedness Innovations (CEPI) in Norway, the Bill and Melinda Gates Foundation, the National Institute of Health (NIH) in Washington and the European Investment Bank (EIB) in Luxembourg.